NCE-1 Intelligence & Market Opportunity

Ibtrozi

Taletrectinib

Anticancer

Oral Capsule

Ibtrozi is a targeted oral therapy for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. This selective ROS1 tyrosine kinase inhibitor received FDA approval in June 2025 with breakthrough therapy designation. Features enhanced CNS penetration for improved efficacy against brain metastases compared to earlier ROS1 inhibitors.

Approval Date

11-Jun-25

NCE-1 Date

11-Jun-29

NCE Date

11-Jun-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

102.09%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

113

2027

227

2028

313

2029

417

2030

511

2031

610

2032

714

Molecule profile

Details & specifications

Molecule

Taletrectinib

Innovator

NUVATION BIO INC

Dosage Form

Oral Capsule

Strength

EQ 200 mg base

Therapeutic Category

Anticancer

Usage

To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets